Studying at the University of Verona
Here you can find information on the organisational aspects of the Programme, lecture timetables, learning activities and useful contact details for your time at the University, from enrolment to graduation.
Study Plan
This information is intended exclusively for students already enrolled in this course.If you are a new student interested in enrolling, you can find information about the course of study on the course page:
Laurea magistrale in Molecular and Medical Biotechnology - Enrollment from 2025/2026The Study Plan includes all modules, teaching and learning activities that each student will need to undertake during their time at the University.
Please select your Study Plan based on your enrollment year.
1° Year
| Modules | Credits | TAF | SSD |
|---|
One course to be chosen among the followingOne course to be chosen among the followingTwo courses to be chosen among the followingThree courses to be chosen among the following2° Year activated in the A.Y. 2019/2020
| Modules | Credits | TAF | SSD |
|---|
| Modules | Credits | TAF | SSD |
|---|
One course to be chosen among the followingOne course to be chosen among the followingTwo courses to be chosen among the followingThree courses to be chosen among the following| Modules | Credits | TAF | SSD |
|---|
| Modules | Credits | TAF | SSD |
|---|
Two courses to be chosen among the following ("Biotechnology in Neuroscience" and "Clinical proteomics" 1st and 2nd year; the other courses 2nd year only)Legend | Type of training activity (TTA)
TAF (Type of Educational Activity) All courses and activities are classified into different types of educational activities, indicated by a letter.
Farming molecolare (2019/2020)
Teaching code
4S003677
Teacher
Coordinator
Credits
6
Language
English
Scientific Disciplinary Sector (SSD)
BIO/15 - PHARMACEUTICAL BIOLOGY
Period
I semestre dal Oct 1, 2019 al Jan 31, 2020.
Learning outcomes
The course aims to give the students notions of the use of recombinant systems for the production of biopharmaceuticals. In particular, the course will be focused on the biomolecular techniques used for the expression of recombinant proteins in prokaryotic and eukaryotic systems and the downstream processing and purification for their large-scale production. The different platforms used for the recombinant expression will be studied and compared. The different US and EU normative procedures for biopharmaceutical commercialization will be evaluated and compared. Specific examples of biopharmaceutical produced in recombinant systems and their therapeutic applications like for vaccines and antibodies will be discussed and studied.
Program
OUTLINE OF THE COURSE OF MOLECULAR FARMING
• L1: General introduction to the course and to Molecular Farming
• L2: Biopharmaceuticals and Drugs. The major Regulatory Agencies.
-Com: Redefining Biopharmaceuticals
• L3: Clinical Trials design
-C: P value
• L4: Biosimilars and Bioequivalence
-R: Key considerations in the preclinical development of biosimilars
• L5-6: Platform for the expression of recombinant protein: Bacterial and
Yeast Cell cultures
-M: Gateway Cloning Technology
-C: Molecular Cloning – Selected Applications in Medicine and Biology
-A: Expression of recombinant proteins in the methlotrophic Yeast Pichia pastoris
• L7: Platform for the expression of recombinant protein: Baculovirus and Insect Cell cultures
-Man: Baculovirus, insect cell expression
• L8-9: Platform for the expression of recombinant protein: Mammalian Cell cultures
-R: Bioreactors and cultivation systems for cell and tissue culture
-C: Cell Culture Bioreactors
-M: overview of transfection Methods
• L10: Platform for the expression of recombinant protein: Transgenic
Animals
• L11: Platform for the expression of recombinant protein: Plant Systems
-R: Plant Molecular Farming: much more than medicine
• L12: Platform for the expression of recombinant protein: Plant Systems, Stable transformation
-R: The increasing Value of plant-made proteins
• L13: Platform for the expression of recombinant protein: Plant Systems, Transient transformation
-R: Viral vectors for the expression of protein in plants
• L14: The antibodies from passive immunization to immunotherapy
-R: Therapeutic antibodies for autoimmunity and inflammation
• L15: Heterologous expression of antibodies
-B: Antibody expression and purification
• L16: Production of antibodies in recombinant systems
-A: Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin
• L17: Post-translational modifications and immunogenicity of biotherapeutics
-R: Bioequivalence and immunogenicity of biopharmaceuticals
• L18: Active immunization: the vaccines
-C: Vaccine Immunology
• L19: Vaccine Manufacturing
-C: Vaccine manufacturing
• L20: Immunological tolerance
• L21: Recombinant production of peptides
-T: Plant viruses for peptide expression in plants
• L22: Techno-economic analysis for the production of antibodies
-A: Techno economic analysis of a transient plant based platform for
monoclonal antibody production
• L23: Downstream processing of biopharmaceuticals
-G: Process Validation: General Principles and Practices
• L24: Production and clinical trials for a specific biopharmaceutical:
references
Examination Methods
The final exam consists in an oral test on the topics of the course (max 27 points) and on a written report on a specific biopharmaceuticals, covering both its production platform/s and its therapeutic use (max 3 points).
